“No-generics” suit against Gilead survives motion to dismiss

A class of indirect purchasers of HIV medication has plausibly alleged that Gilead and other drugmakers conspired to block generic alternatives from the market, a federal court has held.

Get unlimited access to all Global Competition Review content